Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 300-326-6 | CAS number: 93925-25-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Not subacute toxic, evidenced up to the limit test value recommended by guidance, i.e. 1000 mg/kg bw per d, sub-chronic effects unlikely, inhalation and dermal routes irrelevant, baseline toxicity assumed
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- Between 18 October 2011 and 21 December 2011 (in-life phase: 03 to 17 November)
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Valid and conclusive non-guideline study designed as pre-test under GLP, therefore on its own not adequate for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: U.S. NTP 14-Day Toxicity Protocol (as of 2013-01-07, online)
- Deviations:
- yes
- Remarks:
- Only one species, only 3 treatment groups of only 3 test animals per sex per treatment
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Department of Health of Government of the U.K., inspection 19-21 July 2011; no analysis to determine the homogeneity, concentration or stability of the test item admixtures
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Han™:RccHan™:WIST strain animals were supplied from Harlan Laboratories U.K. Ltd., Oxon U.K.
- Age at study initiation: Approximately six to eight weeks
- Weight at study initiation: At the start of treatment the males weighed 227 to 254 g, the females weighed 171 to 189 ,
- Fasting period before study: No
- Housing: The animals were housed in groups of three by sex in solid floor polypropylene cages with stainless steel mesh lids and softwood flake bedding (Datesand Ltd., Cheshire, U.K.).
- Diet: Ad libitum
- Water: Ad libitum
- Acclimation period: 6 d, during which their health status was assessed
ENVIRONMENTAL CONDITIONS
- Temperature: 21 ± 2 °C
- Humidity: 55 ± 15 % relative humidity
- Air changes: 15/h (at least)
- Photoperiod: 12 h dark / 12 h light
IN-LIFE DATES: 03 November 2011 to 17 November 2011 - Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Remarks:
- BP grade
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was prepared at the appropriate concentrations as a suspension in arachis oil BP. The test item was formulated within 2 h of it being administered. It is assumed that the formulation was stable for this duration.
VEHICLE
- Concentration in vehicle: 0, 62.5, 125 and 250 mg/mL
- Amount of vehicle: 4 mL/kg bw; the volume of test and control item administered to each animal was based on the most recent body weight - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- No analysis was conducted to determine the homogeneity, concentration or stability of the test item formulation. This is an exception with regard to GLP and has been reflected in the GLP compliance statement.
- Duration of treatment / exposure:
- 14 d (fourteen consecutive days)
- Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
0, 250, 500 and 1000 mg/kg bw per d
Basis:
actual ingested - No. of animals per sex per dose:
- 3 (altogether 24 test animals were used, whereof 12 were males and 12 females)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels were chosen based on previous toxicity work.
- Rationale for animal assignment: The rat was selected for this study as it is a readily available rodent species historically used in safety evaluation studies and is acceptable to appropriate regulatory authorities. - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: All animals were examined for overt signs of toxicity, ill health or behavioural change immediately before dosing, up to 30 min after dosing and 1 h after dosing. Additional observations were also made 5 h following dosing whenever possible (not at weekends or on public holidays). All observations were recorded.
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: Days 1, 4, 8, 11 and 15
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time ∙ 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
- Food consumption was recorded for each cage group for days 1 to 4, 4 to 8, 8 to 11 and 11 to 15. Food conversion efficiency was calculated retrospectively
WATER CONSUMPTION: Yes
- Time schedule for examinations: Daily; water intake was measured and recorded daily for each cage group. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
All animals were subjected to gross necropsy examination. On completion of the dosing period, all animals were killed by intravenous overdose of a suitable barbiturate agent followed by exsanguination and subjected to an internal and external macroscopic examination.
HISTOPATHOLOGY: No
In absence of gross pathology abnormalities not foreseen in the NTP guidance - Statistics:
- Data were processed to give individual animal/group mean values, standard deviations and incidence of findings where appropriate.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- not examined
- Description (incidence and severity):
- Not foreseen in absence of gross pathology abnormalities
- Histopathological findings: neoplastic:
- not examined
- Description (incidence and severity):
- Not foreseen in absence of gross pathology abnormalities
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Critical effects observed:
- not specified
- Conclusions:
- No 14 d subacute toxicity up to 1000 mg/kg bw per d; no actual NOEAL established
- Executive summary:
The repeated dose toxicity of the test item by oral route was investigated using male and female albino Wistar rats in a GLP-compliant study according to a protocol comparable to the U.S. NTP 14-Day Toxicity Protocol standards. At variance to the guideline only one species and only 3 treatment groups consisting of only 3 test animals per sex per treatment were used. The experiment is deemed valid, conclusive and suitable for assessment with restrictions, but deemed not adequate for assessment of the subacute repeated dose oral toxicity. The purpose of the study was to serve as a pre-test for dose range finding in the available 28 d subacute toxicity study.
Per sex and dose 3 animals were during 14 consecutive days dosed orally by gavage at levels of 0, 250, 500 and 1000 mg/kg bw per d in 4 mL/kg bw (concentrations of 0, 62.5, 125, 250 mg/mL). Clinical signs, body weight change, dietary intake and water consumption were monitored during the study. All animals were subjected to gross necropsy examination.
No effects were recorded and no actual NOAEL could be established.
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Between 05 January 2012 and 13 July 2012 (in-life phase: 13 January 2012 to 24 February)
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Valid and conclusive guideline study under GLP
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- Commission Directive 96/54/EC & Commission Regulation (EC) No 440/2008 of 30 May 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: US EPA: OPPTS 870.3050 (2000)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: METI, MHLW and MOE Guidelines of 21/11/2003.
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Department of Health of Government of the U.K., inspection 19-21 July 2011, histopathology examination phase performed in accordance with the Swiss Ordinance relating to GLP, adopted May 18 2005 [SR 813.112.1]
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Han™:RccHan™:WIST strain animals were supplied from Harlan Laboratories U.K. Ltd., Oxon U.K.
- Age at study initiation: Approximately 6 to 8 weeks
- Weight at study initiation: Males: 201 to 232 g, females: 153 to 190 g.
- Fasting period before study: No
- Housing: The animals were housed in groups of five by sex in solid floor polypropylene cages with stainless steel mesh lids and softwood flake bedding (Datesand Ltd., Cheshire, U.K.).
- Diet: Ad libitum
- Water: Ad libitum
- Acclimation period: 8 d, during which their health status was assessed
ENVIRONMENTAL CONDITIONS
- Temperature: 21 ± 2 °C
- Humidity: 55 ± 15 % relative humidity
- Air changes: 15/h (at least)
- Photoperiod: 12 h dark / 12 h light
IN-LIFE DATES: First day of treatment 13 January 2012, final day of necropsy 24 February 2012 - Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Remarks:
- BP grade
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was prepared at the appropriate concentrations as a suspension in arachis oil BP. On the basis of the analytical investigations, formulations were prepared weekly during the treatment period and stored at approximately 4 ºC in the dark.
VEHICLE
- Concentration in vehicle: 0, 7.5, 75 and 250 mg/mL
- Amount of vehicle: 4 mL/kg bw; the volume of test and control item administered to each animal was based on the most recent body weight - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of each test item formulation were taken and analysed for concentration, stability and homogeneity of the test item at Harlan Laboratories Ltd., Shardlow, U.K., Analytical Services. The results indicate that the prepared formulations were within ± 5 % of the nominal concentration and stable for at least 14 d.
- Duration of treatment / exposure:
- 28 d (twenty-eight consecutive days)
- Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
0, 30, 300 and 1000 mg/kg bw per d; the volume of test and control item administered to each animal was based on the most recent body weight and was adjusted at weekly intervals.
Basis:
actual ingested - No. of animals per sex per dose:
- 5 (altogether 50 test animals were used, whereof 25 were males and 25 females including the highest dose recovery group)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on available toxicity information and compliance with regulatory hazard classification.
- Rationale for selecting satellite groups: To enable the examination of reversibility after exposure, two recovery groups, each of 5 males and 5 females, were treated with the highest dose (1000 mg/kg bw per d) or the vehicle alone for 28 consecutive days and then maintained without treatment for a further 14 d.
- Post-exposure recovery period in satellite groups: 14 d (days 29 to 42) - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Immediately before dosing, up to 30 min post dosing and 1 and 5 h after dosing during the working week. Animals were observed immediately before and after dosing and 1 h after dosing at weekends. During the treatment-free period, animals were observed daily.
- Cage side observations checked: Overt signs of toxicity, ill-health or behavioural change
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Prior to the start of treatment and on days 7, 14, 21 and 26
- Parameters examined: Signs of functional/behavioural toxicity
BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were recorded on day 1 and at weekly intervals thereafter. Body weights were also performed prior to terminal kill and, in the case of recovery group animals, on days 36 and 43 prior to terminal kill.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight per d: No
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes; food consumption was recorded for each cage group at weekly intervals throughout the study. Food conversion efficiency was calculated retrospectively.
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time ∙ 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION: Yes
- Time schedule for examinations: Water intake was observed daily, for each cage group, by visual inspection of the water bottles for any overt changes except from day 19 where water intake was measured gravimetrically. Where possible intergroup difference was detected from day 19, water consumption was continued to be measured and recorded for each cage group until the termination of the study.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Non-recovery group animals at the end of the treatment period (day 28) and recovery group animals at the end of the treatment-free period (day 42); where necessary repeat samples were obtained by cardiac puncture prior to necropsy on days 29 and 43.
- Anaesthetic used for blood collection: No
- Animals fasted: No
- How many animals: All
- Parameters checked: Haemoglobin (Hb), Erythrocyte count (RBC), Haematocrit (Hct), Erythrocyte indices (i.e. mean corpuscular haemoglobin (MCH), mean corpuscular volume (MCV) and mean corpuscular haemoglobin concentration (MCHC)), Total leucocyte count (WBC), Differential leucocyte count (neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), eosinophils (Eos) and basophils (Bas)), Platelet count (PLT), Reticulocyte count (Retic), Prothrombin time (CT) and Activated partial thromboplastin time (APTT)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Non-recovery group animals at the end of the treatment period (day 28) and recovery group animals at the end of the treatment-free period (day 42); where necessary repeat samples were obtained by cardiac puncture prior to necropsy on days 29 and 43
- Animals fasted: No
- How many animals: All
- Parameters checked: Urea Inorganic phosphorus (P), Glucose Gamma glutamyltranspeptidase (γGT), Total protein (Tot.Prot.) Aspartate aminotransferase (ASAT), Albumin Alanine aminotransferase (ALAT), Albumin/Globulin (A/G) ratio (by calculation) Alkaline phosphatase (AP), Sodium (Na+), Creatinine (Creat), Potassium (K+), Triglycerides (Tri), Chloride (Cl-), total cholesterol (Chol), Calcium (Ca++), Total bilirubin (Bili) and Bile acids
URINALYSIS: Yes
- Time schedule for collection of urine: Non-recovery group animals at the end of the treatment period (day 28) and recovery group animals at the end of the treatment-free period (day 42)
- Metabolism cages used for collection of urine: Yes; urine samples were collected overnight by housing the rats in metabolism cages.
- Animals fasted: During overnight housing in metabolism cages animals were maintained under conditions of normal hydration during collection but without access to food.
- How many animals: All
- Parameters examined: Volume, Ketones, Specific Gravity Bilirubin, pH, Urobilinogen, Protein, Blood and Glucose
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During week 4, observations were carried out from approximately 2 h after dosing on each occasion.
- Dose groups that were examined: All
- Battery of functions tested: (1) to (3), see following paragraphs
(1) Behavioural Assessments: Detailed individual clinical observations were performed for each animal using a purpose built arena. The following parameters were observed: Gait and co-ordination, Hyper/Hypothermia, Tremors, Skin colour, Twitches, Respiration, Convulsions, Palpebral closure, Bizarre/Abnormal/Stereotypic behaviour, Urination, Salivation, Defecation, Pilo-erection, Transfer arousal, Exophthalmia, Tail elevation, Lachrymation. The test was developed from the methods used by Irwin (1968) and Moser et al (1988).
(2) Functional Performance Tests: Motor Activity and Forelimb/Hindlimb Grip Strength
Motor Activity: Twenty purpose built 44 infra-red beam automated activity monitors were used to assess motor activity. Animals of one sex were tested at each occasion and were randomly allocated to the activity monitors. The tests were performed at approximately the same time each day, under similar laboratory conditions. The evaluation period was 1 h for each animal. The time in seconds each animal was active and mobile was recorded for the overall hour period and also during the final 20 % of the period (considered to be the asymptotic period, Reiter & MacPhail 1979).
Forelimb/Hindlimb Grip Strength: An automated grip strength meter was used. Each animal was allowed to grip the proximal metal bar of the meter with its forepaws. The animal was pulled by the base of the tail until its grip was broken. The animal was drawn along the trough of the meter by the tail until its hind paws gripped the distal metal bar. The animal was pulled by the base of the tail until its grip was broken. A record of the force required to break the grip for each animal was made. Three consecutive trials were performed for each animal. The assessment was developed from the method employed by Meyer et al (1979).
(3) Sensory Reactivity: Each animal was individually assessed for sensory reactivity to auditory, visual and proprioceptive stimuli. This assessment was developed from the methods employed by Irwin (1968) and Moser et al (1988). The following parameters were observed: Grasp response, Touch escape, Vocalisation, Pupil reflex, Toe pinch, Blink reflex, Tail pinch, Startle reflex and Finger approach.
- Irwin S (1968). Comprehensive Observational Assessment: Ia. A Systematic, Quantitative Procedure for Assessing the Behavioral and Physiologic State of the Mouse. Psychopharmacologia 13:222-57.
- Meyer OA et al (1979). A Method for the Routine Assessment of Fore- and Hindlimb Grip Strength of Rats and Mice. Neurobehavioural Toxicology 1:233-6.
- Moser VC et al (1988). Comparison of Chlordimeform and Carbaryl using a Functional Observational Battery. Fundamental and Applied Toxicology 11:189-206.
- Reiter LW, MacPhail RC (1979). Motor Activity: A Survey of Methods with Potential Use in Toxicology Testing. Neurobehavioral Toxicology 1(1):53-66.
OTHER:
- Thyroid Hormone Assessment
At termination, blood samples were taken from the exsanguination procedure and the serum from each animal was stored at approximately -20 °C.
- Organ Weights
The following organs, removed from animals that were killed either at the end of the dosing period or at the end of the treatment-free period, were dissected free from fat and weighed before fixation:
Adrenals, Liver, Brain, Ovaries, Epididymides, Spleen, Heart, Testes, Kidneys, Thymus, Pituitary (post-fixation), Thyroid/Parathyroid (post fixation), Prostate and Seminal Vesicles (with coagulating glands and fluids) and Uterus with Cervix - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
On completion of the dosing period, or in the case of recovery group animals, at the end of the treatment-free period, all animals were killed by intravenous overdose of sodium pentobarbitone followed by exsanguination. All animals were subjected to a full external and internal examination, and any macroscopic abnormalities were recorded.
HISTOPATHOLOGY: Yes
Samples of the following tissues were removed from all animals and preserved in buffered 10 % formalin except where stated:
Adrenals, Ovaries, Aorta (thoracic), Pancreas, Bone & bone marrow (femur including stifle joint), Pituitary, Bone & bone marrow (sternum) Prostate, Brain (including cerebrum, cerebellum and pons), Rectum, Salivary glands (submaxillary), Caecum, Sciatic nerve, Colon, Seminal vesicles (with coagulating, Duodenum, Epididymides, Skin (hind limb), Eyes, Spinal cord (cervical, mid thoracic and lumbar), Gross lesions, Heart, Spleen, Ileum, Stomach, Jejunum, Testes, Kidneys, Thymus, Liver, Thyroid/Parathyroid, Lungs (with bronchi), Trachea, Lymph nodes (mandibular and mesenteric), Urinary bladder, Mammary gland, Uterus & Cervix, Muscle (skeletal), Vagina and Oesophagus - Statistics:
- Data were processed to give summary incidence or group mean and standard deviation values were appropriate. Where considered appropriate, quantitative data was subjected to statistical analysis to detect the significance of intergroup differences from control; statistical significance was achieved at a level of p < 0.05. Statistical analysis was performed on the following parameters: Grip Strength, Motor Activity, Body Weight Change, Haematology, Blood Chemistry, Urinalysis (Volume and Specific Gravity), Absolute Organ Weights, Body Weight-Relative Organ Weights.
Data were analysed using the decision tree from the Provantis™ Tables and Statistics Module as detailed below:
Where appropriate, data transformations were performed using the most suitable method. The homogeneity of variance from mean values was analysed using Bartlett’s test. Intergroup variance were assessed using suitable ANOVA, or if required, ANCOVA with appropriate covariates. Any transformed data were analysed to find the lowest treatment level that showed a significant effect, using the Williams Test for parametric data or the Shirley Test for non-parametric data. If no dose response was found, but the data shows non-homogeneity of means, the data were analysed by a stepwise Dennett’s (parametric) or Steel (non-parametric) test to determine significant difference from the control group. Where the data were unsuitable for these analyses, pair-wise tests was performed using the Student t-test (parametric) or the Mann-Whitney U test (non-parametric). - Clinical signs:
- no effects observed
- Description (incidence and severity):
- Isolated incidences of increased salivation at 1000 mg/kg bw per d, considered not to be of toxicological importance
- Mortality:
- no mortality observed
- Description (incidence):
- Isolated incidences of increased salivation at 1000 mg/kg bw per d, considered not to be of toxicological importance
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Intergroup differences detected in erythrocyte and haematocrit, considered not to be of toxicological importance
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Intergroup differences detected in urea, cholesterol, chloride concentration, phosphorus, alkaline phosphatase and creatinine, considered not to be of toxicological importance
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- Intergroup differences detected in forelimb grip strength and overall activity, considered to be of no toxicological importance
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Intergroup differences detected in pituitary and thyroid weight, considered not to be of toxicological importance
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Macroscopic intergroup differences, considered not to be of toxicological importance
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Findings recorded were within the range of normal background lesions which may be recorded in rats of the strain and age used
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- No differences between treated and control animals were observed or were considered not to be indicative of test item toxicity as explained below:
Clinical signs
- Four males treated with 1000 mg/kg bw per d showed isolated incidents of increased salivation on either days 21 or 25 and two females from this treatment group showed increased salivation on day 21 only. Observations of this nature are commonly observed following the oral administration of an unpalatable or slightly irritant test item formulation and in isolation are considered not to be of toxicological importance.
Haematology
- Males treated with 1000 mg/kg bw per d showed statistically significant increases in erythrocyte count and haematocrit. The majority of individual values were within the normal ranges for rats of the strain and age used and in the absence of any associated changes the intergroup differences were considered not to be of toxicological importance.
Clinical Chemistry
- Males treated with 1000 mg/kg bw per d showed statistically significant increases in urea and cholesterol, with the effect in cholesterol also extending to 300 mg/kg bw per d males. The majority of individual values were within the normal ranges for rats of the strain and age used and in the absence of any associated histology changes the intergroup differences were considered not to be of toxicological importance.
- Recovery 1000 mg/kg bw per d males showed a statistically significant increase in chloride concentration following 14 d without treatment. All individual values were within the normal range for rats of the strain and age used and in the absence of a similar result in animals at the end of the treatment period the intergroup difference was considered not to be of toxicological significance.
- Females from all treatment groups showed a statistically significant increase in phosphorus. Females treated with 1000 and 300 mg/kg bw per d and recovery 1000 mg/kg bw per d females showed a reduction in alkaline phosphatase. All individual values were within the normal ranges for rats of the strain and age used and in the absence of a true dose related response the intergroup differences were considered not to be of toxicological importance.
- Females treated with 1000 and 300 mg/kg bw per d also showed a statistically significant increase in creatinine. The majority of individual values were within the normal range for rats of the strain and age used and in the absence of any associated histology changes the intergroup differences were considered not to be of toxicological importance.
Neurobehaviour (Functional Observations)
A. Behavioural Assessments:
- All inter and intra group differences in urination, defecation and transfer arousal scores were considered to be a result of normal variation for rats of the strain and age used, and the differences were of no toxicological importance.
B. Functional Performance Tests:
- Males treated with 30 mg/kg bw per d showed a statistically significant increase in overall motor activity. In the absence of a true dose related response or any supporting clinical observations to suggest an effect of neurotoxicity, the finding was considered to be of no toxicological significance.
- Males treated with 1000 mg/kg bw per d showed a statistically significant increase in mean fore limb grip strength whilst females from this treatment group showed a statistically significant reduction in mean fore limb grip strength. All of the individual values were within the normal range for rats of the strain and age used and in the absence of any supporting clinical observations to suggest an effect of neurotoxicity, the intergroup differences were considered to be of no toxicological significance.
Thyroid Hormone Assessment
No treatment-related effects on the pituitary-thyroid axis were identified, therefore these samples were discarded.
Organ Weights
- Females from all treatment groups showed statistically significant reductions in thyroid weight. Females treated with 1000 mg/kg bw per d also showed a statistically significant increase in absolute and relative pituitary weight. In the absence of any associated histology correlates the intergroup differences were considered not to be of toxicological importance.
Necropsy
- One female treated with 300 mg/kg bw per d had an enlarged and fluid filled uterus. Microscopic examination of this female revealed cornual dilation. In the absence of a similar effect detected in females treated with 1000 mg/kg bw per d the macroscopic finding was considered not to be of toxicological importance.
- One control male had small testes and epididymides. Microscopic examination revealed azoospermia in both epididymides and tubular degeneration in both testes. Observations of this nature are occasionally observed in control males and therefore in the absence of treatment are considered of no toxicological importance. - Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Critical effects observed:
- no
- Conclusions:
- No 28 d subacute toxicity up to 1000 mg/kg bw per d, no actual NOEAL established
- Executive summary:
The repeated dose toxicity of the test item by oral route was investigated in a GLP-compliant study using male and female Wistar rats according to the EU B.7 (2008), OECD TG 407 (2008) and OPPTS 870.3050 (2000) protocols and compliant to the Japanese Ministry of Economy Trade and Industry (METI), Ministry of Health, Labour and Welfare (MHLW) and Ministry of the Environment (MOE) Guidelines of 21 November 2003 for a twenty-eight day repeat dose oral toxicity study as required by the Law Concerning the Evaluation of Chemical Substances and Regulation of their Manufacture, etc. (Chemical Substance Control Law) 1973 of Ministry of International Trade and Industry (MITI) amended 2004. The experiment is deemed valid, conclusive and thus suitable for assessment without restrictions.
The test item was administered by gavage to three groups, each of five male and five female Wistar rats, for twenty-eight consecutive days, at dose levels of 30, 300 and 1000 mg/kg bw per d. A control group of five males and five females was treated with vehicle alone (arachis oil BP). Two recovery groups, each of five males and five females, were treated with the high dose (1000 mg/kg bw per d) or the vehicle alone for twenty-eight consecutive days and then maintained without treatment for a further 14 d. Clinical signs, body weight change and food and water consumption were monitored during the study. Haematology, blood chemistry and urinalysis were evaluated for all non-recovery group animals at the end of the treatment period and for all recovery group animals at the end of the treatment-free period.
There were no unscheduled deaths during the study and no clinically observed signs of toxicity were detected. The behavioural assessment revealed no treatment-related changes and there were no toxicologically significant changes in functional performance. The sensory reactivity and the body weight development were not different in treated animals when compared to controls and food and water consumption showed as well no intergroup differences. The haematological investigation, blood chemistry and urinalysis showed no toxicologically significant effects in the parameters examined. The organ weights were comparable between treatments and control and finally no toxicologically significant macroscopic abnormalities were detected during the Necropsy and Histopathology.
In conclusion the administration of the test item up to a dose of 1000 mg/kg bw per d, did not result in any toxicologically significant effects. No actual NOAEL could be established as no effects up to the maximum dose level recommended by the test guidance was recorded. On the basis of this study no indication for classification is given.
- Endpoint:
- sub-chronic toxicity: oral
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- a sub-chronic toxicity study (90 days) does not need to be conducted because the substance is unreactive, insoluble and not inhalable and there is no evidence of absorption and no evidence of toxicity in a 28-day 'limit test' and human exposure is limited
- Reason / purpose for cross-reference:
- reference to other study
- Critical effects observed:
- not specified
Referenceopen allclose all
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Altogether 3 studies reporting effects of subacute 28-d oral dosing of the submission item are available. All experiments were conducted under GLP using rats and revealed no effects (NOAEL ≥ 1000 mg/kg bw per d). Dunster & Watson 2012 (Harlan Report no. 41103273 is the key study as it is fully complies with the REACH, Annex IX, 8.6.1. requirements. Dunster 2011 (Harlan Report no. 41103272) represents the GLP pre-test for Dunster & Watson 2012 and is limited to a 14-d exposure. Finally the study of Toot (2012, WIL Research Report no. WIL-168198), a screening test for toxicity to reproduction and development, reports effects of repeated dosing up to 53 days.
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Reason / purpose for cross-reference:
- reference to other study
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
- Reason / purpose for cross-reference:
- reference to other study
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Reason / purpose for cross-reference:
- reference to same study
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Reason / purpose for cross-reference:
- reference to same study
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Experimental data from subacute repeated dose toxicity by the oral route studies are available. Testing on other routes and subchronic repeated dose toxicity has been waived in accordance with column 2 restrictions.
First, as a pre-test, the repeated dose toxicity by oral route was investigated in a GLP-compliant study (Dunster 2011, Harlan Report no. 41103272) using male and female albino Wistar rats according to a protocol comparable to the U.S. NTP 14-Day Toxicity Protocol standards. No difference to the control was observed after 14 d exposure at concentrations up to 1000 mg/kg bw per d, the limit test value recommended by OECD TG 407 (2008). Therefore the dose regimen in definitive study was chosen up to this limit.
Then, the repeated dose toxicity by oral route was investigated in a GLP-compliant study (Dunster & Watson 2012, Harlan Report no. 41103273) using male and female Wistar rats according to the EU B.7 (2008), OECD TG 407 (2008) and OPPTS 870.3050 (2000) protocols and compliant to the Japanese METI, MHLW and MOE Guidelines (2003). The experiment is deemed valid, conclusive and thus suitable for assessment without restrictions. The submission item was administered by gavage to three groups, each of five male and five female Wistar rats, for twenty-eight consecutive days, at dose levels of 30, 300 and 1000 mg/kg bw per d. A control group of five males and five females was treated with vehicle alone (arachis oil BP). Two recovery groups, each of five males and five females, were treated with the high dose (1000 mg/kg bw per d) or the vehicle alone for twenty-eight consecutive days and then maintained without treatment for a further 14 d. Clinical signs, body weight change and food and water consumption were monitored during the study. Haematology, blood chemistry and urinalysis were evaluated for all non-recovery group animals at the end of the treatment period and for all recovery group animals at the end of the treatment-free period. There were no unscheduled deaths during the study and no clinically observed signs of toxicity were detected. The behavioural assessment revealed no treatment-related changes and there were no toxicologically significant changes in functional performance. The sensory reactivity and the body weight development were not different in treated animals when compared to controls and food and water consumption showed as well no intergroup differences. The haematological investigation, blood chemistry and urinalysis showed no toxicologically significant effects in the parameters examined. The organ weights were comparable between treatments and control and finally no toxicologically significant macroscopic abnormalities were detected during the Necropsy and Histopathology. In conclusion the administration of the submission item up to a dose of 1000 mg/kg bw per d, did not result in any toxicologically significant effects. No actual NOAEL could be established as no effects up to the maximum dose level recommended by the test guidance was recorded. This result supports the assumption of absence of a specific mode of action and thus baseline toxicity can be assumed.
No experimental data from a study on repeated dose toxicity by inhalation are available. Testing has been waived in accordance with column 2 restrictions. In view of the low vapour pressure (0.00043 Pa at 25 °C, Tremain & Atwal 2011, Harlan Report no. 41103264) leading to low volatilization and the expected absence of airborne forms of the submission item in the supported uses, inhalation is deemed an irrelevant route.
No experimental data from a study on repeated dose toxicity by dermal route are available. Testing has been waived in accordance with column 2 restrictions. According to the recommended risk mitigation measurements repeated or regular skin contact is unlikely and the high lipophilicity level (Log Kow > 9.4, Fox & White 2012, Harlan Report no. 41103263) represents an absorption barrier.
Justification for selection of repeated dose toxicity via oral
route - systemic effects endpoint:
The study of Dunster & Watson (2012, Harlan Report no. 41103273)
represents the only available experimental data collected in accordance
with an adequate guideline.
Justification for classification or non-classification
Based on the available data, the submission item is not classified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)